SBI Securities’s InMed Pharmaceuticals INM Stock Holding History

SBI Securities’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$465	Hold	300	–	–	﹤0.01%	3056
2026 Q1	$193	Hold	300	–	–	﹤0.01%	3233
2025 Q4	$318	Hold	300	–	–	﹤0.01%	3047
2025 Q3	$657	Hold	300	–	–	﹤0.01%	2865
2025 Q2	$975	Hold	300	–	–	﹤0.01%	2689
2025 Q1	$621	Buy	+300	New	+$1K	﹤0.01%	2778

Other funds holding INM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UFM

Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SBI Securities's INM Position: Q2 2026 in Review

SBI Securities held its InMed Pharmaceuticals (INM) position steady in Q2 2026 at 300 shares worth $465. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

SBI Securities first reported a position in INM in Q1 2025 and has held it in 6 quarters since. The position peaked at $975 in Q2 2025. 20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

SBI Securities held 300 shares of InMed Pharmaceuticals worth $465 as of Q2 2026.
SBI Securities left its InMed Pharmaceuticals share count unchanged in Q2 2026.
InMed Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3056 holding.
SBI Securities first reported a position in InMed Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
SBI Securities's InMed Pharmaceuticals position peaked at $975 in Q2 2025.
20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.